New Data With B-MS' Serzone

2 July 1997

Bristol-Myers Squibb presented data at the WCBP which demonstrated thatSerzone (nefazodone) is effective in the treatment of severely-depressed hospitalized patients.

81 patients received either Serzone (100-600mg/day) or placebo for a period of six weeks. Serzone was found to be superior to placebo on the Hamilton Depression Rating Scale, with a mean change of 13.5 in Serzone-treated patients, and 6.1 in placebo receivers. The number of patients experiencing at least a 50% decrease in the HAM-D score was 54% of the Serzone group versus 18% of the placebo group. Significant differences were noted by week one on a number of rating scales.

Of the Serzone-treated group, 10% discontinued due to side effects versus 13% of the placebo group. In addition, 29% of Serzole receivers and 48% of those taking placebo discontinued due to lack of clinical effect.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight